老年肿瘤患者多重用药的研究进展  

Research advancement of the polypharmacy in elderly patients with cancer

作　　者：宋长城[1] 张婷[1] 吕颖鉞 

机构地区：[1]解放军第454医院老年医学科,江苏南京210002

出　　处：《现代肿瘤医学》2017年第4期650-653,共4页Journal of Modern Oncology

摘　　要：老年肿瘤患者由于服用多种药物,包括抗肿瘤药物、支持治疗药物,以及治疗共病药物,存在药物相关问题的风险。再者,许多老年肿瘤患者自购非处方药物及营养保健品。因此,多重用药在老年肿瘤患者中非常普遍。多重用药及因增龄而导致的药物代谢动力学及药效学的改变对老年肿瘤患者造成诸多危害,如药物不良反应增加,病死率和患病率上升,老年综合征发生率升高,以及医疗费用上涨,住院次数增加,住院时间延长。因此,老年肿瘤患者处方比较复杂且面临诸多挑战。Elderly patients with cancer who have multiple comorbid disorders are at a considerable increased risk of drug- related problems becausethey typically receive numerous medications,including antineoplastic agents,drugs for supportive care,and medications for comorbid illnesses. Moreover,these patients might also take self- prescribed over- the- counter drugs or complementary and alternative medicines. Therefore,polypharmacy is very common in elderly patients with cancer who are particularly at risk for adverse drug events associated with polypharmacy and drug- drug interactions due to patients＇ altered pharmacokinetic / pharmacodynamic status. Inappropriate use of drugs in elderly patients with cancer have an adverse impact on several individual health outcomes,such as increasing the prevalence of adverse drug reactions,morbidity and mortality,and geriatric syndromes,as well as on health care systems,such as increased costs and hospitalization and longer hospital stays. Prescribing for older patients with cancer is challenging and complex. Challenges for the doctors who treat elderly patients with cancer include identification of what drugs are actually being taken by the patient,avoidance or management of any adverse effects or drug interactions,and reassessing the patient＇s overall treatment.

关 键 词：肿瘤 老年 多重用药 

分 类 号：R730.5[医药卫生—肿瘤]